423PPhase I study of IDO1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with atezolizumab in Japanese patients with advanced solid tumors. (23rd October 2018) - Yamamoto, N; Fujiwara, Y; Kondo, S; Iwasa, S; Yonemori, K; Shimomura, A; Kitano, S; Shimizu, T; Koyama, T; Ebata, T; Sato, N; Nakai, K; et al.